With the advent of the molecular biology revolution and the human genome project in the 1990s there was a historic shift toward target-based drug development. Target-based drug development, or TDD, relies on prior knowledge of disease mechanisms and targets before development can begin.
Our CSO, Dr. Chris Hopkins presented at DR. GPCR SUMMIT 2020 on why C. elegans is an ideal model to study the underlying principles of GPCRs.
Dr. Vollmer shares his experience working with us and how the Longevity Platform delivers the results he needs within his timeline and budget.
Tune in weekly to our virtual series “Seventeen Minutes of Science” every Tuesday at 11am PST / 2pm ET where we go live on Facebook with a new guest each week to talk about how science and biotechnology is woven into their lives for (you guessed it) 17 minutes! This week on 17 Minutes of …
Our co-founder discusses how looking outside the box of conventional antiviral drugs has been a fruitful approach to seeking new drugs against SARS-CoV-2.
Stuck at home with nothing to do during this quarantine? Restless to still be learning and interacting with other scientists? You’re in luck! You can now tune in weekly to our virtual series “Seventeen Minutes of Science”. Every Tuesday at 11am PST / 2pm ET we will go live on Facebook to talk about science …
Seventeen Minutes of Science: Spreading out from Kendall (Episode 6) Read More »
Sign up for our upcoming webinar to learn more about our Longevity Platform and how it can benefit you! Title: A Shortcut to Understanding Longevity: A Rapid in vivo Analysis of a Compound’s Effect on Health and Aging Date: Wednesday February 12th, 2020 Time: 11am PST/2pm ET Agenda: Who are we? Healthy Aging: compounds for improving longevity and …
[New Webinar] A Shortcut to Understanding Longevity Read More »
While advances in molecular imaging, high-throughput screening, genomics and techniques like CRISPR-Cas9 gene editing have dramatically enhanced our understanding of the human body and disease, the pace of advancing new treatments for those diseases has lagged behind significantly. One way to shorten the time between laboratory discoveries and available new drugs is to use animal …
Zebrafish and C. elegans in ALS: tightening the bench-to-clinic gap Read More »
The wMicroTracker is a great product to add to your drug screening toolkit. Check out the application sheet below to see how easy it is to use and how it can positively impact your research.
Non-mammalian model organisms are typically used in early research to deliver fast answers to a discovery problem. The most popular model organisms in biological and biomedical research are the fruit fly Drosophila melanogaster, the zebrafish and the nematode C. elegans. We provide an overview of the advantages and limitations of these organisms as models for human diseases in this post
